

# Melissa E Murray

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1139008/publications.pdf>

Version: 2024-02-01

231  
papers

21,847  
citations

11608

70  
h-index

11030

137  
g-index

265  
all docs

265  
docs citations

265  
times ranked

18186  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study and functional validation implicates JADE1 in tauopathy. <i>Acta Neuropathologica</i> , 2022, 143, 33-53.	3.9	19
2	Alzheimer's disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
3	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	1.4	3
4	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	2.4	14
5	A computational model of neurodegeneration in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1643.	5.8	32
6	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without <i>GRN</i> mutations. <i>Brain</i> , 2022, 145, 2472-2485.	3.7	6
7	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2022, 143, 571-583.	3.9	3
8	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. <i>Acta Neuropathologica</i> , 2022, 144, 159-160.	3.9	14
9	Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	5
10	Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. <i>Acta Neuropathologica</i> , 2022, 144, 27-44.	3.9	67
11	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. <i>Acta Neuropathologica</i> , 2022, 144, 1117-1125.	3.9	11
12	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	0
13	Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 417-430.	0.4	34
14	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	1.5	11
15	The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 141, 631-650.	3.9	75
16	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2021, 141, 667-680.	3.9	5
17	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	1.2	7
18	Loss of <i>Tmem106b</i> leads to cerebellum Purkinje cell death and motor deficits. <i>Brain Pathology</i> , 2021, 31, e12945.	2.1	8

#	ARTICLE	IF	CITATIONS
19	New insights into atypical Alzheimer's disease in the era of biomarkers. <i>Lancet Neurology</i> , The, 2021, 20, 222-234.	4.9	214
20	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. <i>Alzheimer's and Dementia</i> , 2021, 17, 1554-1574.	0.4	114
21	Long-read targeted sequencing uncovers clinicopathological associations for <i>C9orf72</i> -linked diseases. <i>Brain</i> , 2021, 144, 1082-1088.	3.7	17
22	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 2311.	5.8	44
23	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	1.2	8
24	The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021, 17, 2043-2055.	0.4	34
25	Genome-wide analysis identifies a novel LINC-PINT splice variant associated with vascular amyloid pathology in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 93.	2.4	9
26	Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. <i>Molecular Cell</i> , 2021, 81, 4209-4227.e12.	4.5	84
27	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- $\beta$ PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.5	10
28	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. <i>Science Translational Medicine</i> , 2021, 13, eabc9375.	5.8	37
29	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
30	Neuropathologic underpinnings of PET and fluid biomarker measures. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
31	Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 225.	4.5	50
32	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020, 16, 561-571.	0.4	113
33	$\beta$ -Amyloid PET and neuropathology in dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e282-e291.	1.5	65
34	Association of <i>ABI3</i> and <i>PLCG2</i> missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. <i>Acta Neuropathologica Communications</i> , 2020, 8, 172.	2.4	8
35	Neuroimaging in dementias. , 2020, , 187-197.		0
36	Sensitivity-Specificity of Tau and Amyloid $\beta$ Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	2.8	32

#	ARTICLE	IF	CITATIONS
37	Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 1372-1383.	0.4	34
38	Neuropathologically defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039957.	0.4	0
39	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. <i>Acta Neuropathologica Communications</i> , 2020, 8, 218.	2.4	8
40	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	3.7	45
41	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	1.5	81
42	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.5	27
43	Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. <i>Brain</i> , 2020, 143, 1905-1919.	3.7	44
44	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. <i>Neurology</i> , 2020, 95, e35-e45.	1.5	9
45	Subtypes of dementia with Lewy bodies are associated with $\alpha$ -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.5	47
46	Confirmation of <sup>123</sup> I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1628-1635.	2.8	18
47	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	1.5	17
48	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	1.2	14
49	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	1.8	4
50	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. <i>Neurobiology of Aging</i> , 2020, 92, 92-97.	1.5	13
51	Pick's disease: clinicopathologic characterization of 21 cases. <i>Journal of Neurology</i> , 2020, 267, 2697-2704.	1.8	17
52	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2019, 15, 1218-1228.	0.4	34
53	Reply: LATE to the PART-y. <i>Brain</i> , 2019, 142, e48-e48.	3.7	11
54	Evaluation of Associations of Alzheimer's Disease Risk Variants that Are Highly Expressed in Microglia with Neuropathological Outcome Measures. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 659-666.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. <i>Acta Neuropathologica Communications</i> , 2019, 7, 150.	2.4	40
56	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1782-1796.	1.7	20
57	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1655-1662.	2.2	14
58	Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1037-1048.	1.2	22
59	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	3.7	37
60	The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals. <i>Neurobiology of Aging</i> , 2019, 77, 26-36.	1.5	51
61	Association of <i>MAPT</i> H1 subhaplotypes with neuropathology of lewy body disease. <i>Movement Disorders</i> , 2019, 34, 1325-1332.	2.2	15
62	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
63	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.5	62
64	Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa. <i>Alzheimer's and Dementia</i> , 2019, 15, 799-806.	0.4	14
65	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	3.7	873
66	Association of <i>MAPT</i> Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. <i>JAMA Neurology</i> , 2019, 76, 710.	4.5	39
67	Ethnoracial differences in Alzheimer's disease from the Florida Autopsied Multi-Ethnic (FLAME) cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 635-643.	0.4	29
68	Genome-wide analyses as part of the international FTL-DTP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTL. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	3.9	90
69	Selective loss of cortical endothelial tight junction proteins during Alzheimer's disease progression. <i>Brain</i> , 2019, 142, 1077-1092.	3.7	120
70	Mild cognitive impairment associated with eventual Lewy body disease pathology: Clinical characterization of 75 patients. <i>Journal of the Neurological Sciences</i> , 2019, 405, 20.	0.3	0
71	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
72	Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. <i>Acta Neuropathologica</i> , 2019, 137, 227-238.	3.9	65

#	ARTICLE	IF	CITATIONS
73	Multisite study of the relationships between <i>antemortem</i> [ <sup>11</sup> C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216.	0.4	155
74	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2019, 121, 327-337.	2.1	79
75	APOE4-mediated amyloid- $\beta^2$ pathology depends on its neuronal receptor LRP1. <i>Journal of Clinical Investigation</i> , 2019, 129, 1272-1277.	3.9	96
76	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018, 14, 563-575.	0.4	98
77	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	1.2	19
78	Tau-negative amnesic dementia masquerading as Alzheimer disease dementia. <i>Neurology</i> , 2018, 90, e940-e946.	1.5	24
79	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 99-103.	1.1	22
80	Clinicopathological and <sup>123</sup> I- $\beta$ -FP-CIT SPECT correlations in patients with dementia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 376-381.	1.7	11
81	Relationships between lewy and tau pathologies in 375 consecutive non-Alzheimer's olfactory bulbs. <i>Movement Disorders</i> , 2018, 33, 333-334.	2.2	1
82	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	3.7	218
83	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	4.9	97
84	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. <i>Brain</i> , 2018, 141, 1201-1217.	3.7	67
85	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	4.5	15
86	The limbic and neocortical contribution of $\alpha$ -synuclein, tau, and amyloid $\beta^2$ to disease duration in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2018, 14, 330-339.	0.4	69
87	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 352-366.	0.4	116
88	Pittsburgh compound B (PIB) PET imaging of meningioma and other intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2018, 136, 373-378.	1.4	9
89	F101: NEUROPATHOLOGIC HETEROGENEITY OF ALZHEIMER'S DISEASE AND RELATED DISORDERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P199.	0.4	0
90	Association of Apolipoprotein E $\epsilon$ 4 With Transactive Response DNA-Binding Protein 43. <i>JAMA Neurology</i> , 2018, 75, 1347.	4.5	60

#	ARTICLE	IF	CITATIONS
91	APOE $\epsilon$ 2 is associated with increased tau pathology in primary tauopathy. <i>Nature Communications</i> , 2018, 9, 4388.	5.8	100
92	Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2018, 136, 873-885.	3.9	69
93	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. <i>Autophagy</i> , 2018, 14, 1404-1418.	4.3	87
94	Loss of <i>Tmem106b</i> is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. <i>Acta Neuropathologica Communications</i> , 2018, 6, 42.	2.4	20
95	Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 63.	2.4	79
96	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1227-1233.	1.2	20
97	Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2018, 136, 709-727.	3.9	47
98	<i>APOE</i> $\epsilon$ 4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. <i>Neurology</i> , 2018, 91, e1182-e1195.	1.5	122
99	Diffuse Lewy body disease manifesting as corticobasal syndrome. <i>Neurology</i> , 2018, 91, e268-e279.	1.5	37
100	The neuropathology of dementia.. , 2018, , 41-66.		1
101	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	3.9	125
102	Frontotemporal dementia with the V337M <i>MAPT</i> mutation. <i>Neurology</i> , 2017, 88, 758-766.	1.5	76
103	Approach to atypical Alzheimer's disease and case studies of the major subtypes. <i>CNS Spectrums</i> , 2017, 22, 439-449.	0.7	63
104	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.4	423
105	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. <i>JAMA Neurology</i> , 2017, 74, 718.	4.5	107
106	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. <i>Acta Neuropathologica</i> , 2017, 134, 255-269.	3.9	76
107	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
108	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	1.5	158

#	ARTICLE	IF	CITATIONS
109	Multisite Assessment of Aging-Related Tau Astroglialopathy (ARTAG). <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 605-619.	0.9	38
110	Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. <i>Human Molecular Genetics</i> , 2017, 26, 1407-1418.	1.4	78
111	Brain tau deposition linked to systemic causes of death in normal elderly. <i>Neurobiology of Aging</i> , 2017, 50, 163-166.	1.5	2
112	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7
113	Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease. <i>Movement Disorders</i> , 2017, 32, 1584-1593.	2.2	15
114	Amyloid PET scan. <i>Neurology</i> , 2017, 89, 2029-2030.	1.5	6
115	Parkinson's disease susceptibility variants and severity of Lewy body pathology. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 79-84.	1.1	17
116	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	4.9	159
117	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. <i>Neuron</i> , 2017, 95, 808-816.e9.	3.8	493
118	Abnormal expression of homeobox genes and transthyretin in <i>C9ORF72</i> expansion carriers. <i>Neurology: Genetics</i> , 2017, 3, e161.	0.9	12
119	AV-1451 tau and $^{125}$ I-amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	2.8	152
120	FTDP-17 with Pick body-like inclusions associated with a novel tau mutation, p.E372G. <i>Brain Pathology</i> , 2017, 27, 612-626.	2.1	11
121	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.4	41
122	Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 200-214.	1.8	49
123	[S3a0103]: ATYPICAL ALZHEIMER'S DISEASE PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2017, 13, P877.	0.4	0
124	MAPT haplotype diversity in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 30, 40-45.	1.1	23
125	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 5-14.	1.2	17
126	IC0105: Neuropathologic Features of AV1451 TAU Pet Autoradiography in Dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, P4.	0.4	0



#	ARTICLE	IF	CITATIONS
127	O3â€04â€04: Alzheimer's Disease May Not be More Common in Women; Men May be More Commonly Misdiagnosed. <i>Alzheimer's and Dementia</i> , 2016, 12, P292.	0.4	1
128	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 862-871.	0.4	93
129	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2016, 45, 107-108.	1.5	21
130	Tremor in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 93-97.	1.1	17
131	Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2016, 132, 225-234.	3.9	73
132	Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. <i>Acta Neuropathologica</i> , 2016, 132, 197-211.	3.9	49
133	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , 2016, 2, e85.	0.9	16
134	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2016, 26, 264-268.	1.0	3
135	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	2.4	388
136	LRRK2 variation and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 98-103.	1.1	30
137	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	3.9	116
138	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	1.4	249
139	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Nature Communications</i> , 2016, 7, 11253.	5.8	174
140	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.4	32
141	Case Studies Illustrating Focal Alzheimerâ€™s, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia. <i>Neurologic Clinics</i> , 2016, 34, 699-716.	0.8	3
142	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	2.2	32
143	Quantitative characterization of brain Î²-amyloid in 718 normal subjects using a joint PiB/FDG PET image histogram. , 2016, , .		0
144	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. <i>Acta Neuropathologica</i> , 2016, 131, 571-585.	3.9	244

#	ARTICLE	IF	CITATIONS
145	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	3.9	380
146	C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. <i>Nature Neuroscience</i> , 2016, 19, 668-677.	7.1	268
147	Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 43-50.	1.2	44
148	Evaluating pathogenic dementia variants in posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2016, 37, 38-44.	1.5	23
149	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. <i>American Journal of Neurodegenerative Disease</i> , 2016, 5, 94-101.	0.1	4
150	Transmission of Soluble and Insoluble $\tau$ -Synuclein to Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 1158-1169.	0.9	14
151	Transmission of Soluble and Insoluble $\tau$ -Synuclein to Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 1158-1169.	0.9	25
152	TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. <i>Annals of Neurology</i> , 2015, 78, 697-709.	2.8	96
153	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. <i>Molecular Neurodegeneration</i> , 2015, 10, 46.	4.4	58
154	Neuroimaging in Dementias. , 2015, , 107-118.		0
155	A novel tau mutation, p.K317N, causes globular glial tauopathy. <i>Acta Neuropathologica</i> , 2015, 130, 199-214.	3.9	38
156	F3-02-01: The relationship of primary age-related tauopathy (PART) to snap: Controversy or parallel?. , 2015, 11, P212-P213.		1
157	Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology. <i>Nature Medicine</i> , 2015, 21, 219-220.	15.2	15
158	Clinicopathologic and <sup>11</sup> C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	3.7	270
159	A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2015, 130, 145-157.	3.9	24
160	Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. <i>Nature Neuroscience</i> , 2015, 18, 1175-1182.	7.1	330
161	<i>C9ORF72</i> repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. <i>Science</i> , 2015, 348, 1151-1154.	6.0	332
162	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. <i>Acta Neuropathologica</i> , 2015, 130, 77-92.	3.9	267

#	ARTICLE	IF	CITATIONS
163	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. <i>Acta Neuropathologica</i> , 2015, 130, 863-876.	3.9	104
164	Intraneuronal amyloid- $\beta$ accumulation in basal forebrain cholinergic neurons: a marker of vulnerability, yet inversely related to neurodegeneration. <i>Brain</i> , 2015, 138, 1444-1445.	3.7	3
165	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. <i>Acta Neuropathologica</i> , 2015, 130, 559-573.	3.9	89
166	Role for the microtubule-associated protein tau variant p.A152T in risk of $\beta$ -synucleinopathies. <i>Neurology</i> , 2015, 85, 1680-1686.	1.5	31
167	Mitochondrial ATP synthase activity is impaired by suppressed <i>O</i> -GlcNAcylation in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2015, 24, 6492-6504.	1.4	74
168	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	1.5	113
169	Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLTDP Type A. <i>Acta Neuropathologica</i> , 2015, 129, 53-64.	3.9	67
170	FUS is Phosphorylated by DNA-PK and Accumulates in the Cytoplasm after DNA Damage. <i>Journal of Neuroscience</i> , 2014, 34, 7802-7813.	1.7	129
171	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.5	45
172	<i>LRRK2</i> exonic variants and risk of multiple system atrophy. <i>Neurology</i> , 2014, 83, 2256-2261.	1.5	46
173	O1-12-03: THAL AMYLOID PHASE: CLINICOPATHOLOGIC AND PIB-PET IMPLICATIONS OF AD PATHOPHYSIOLOGY. , 2014, 10, P153-P155.		1
174	Quantitative characterization of brain $\beta$ -amyloid using a joint PiB/FDG PET image histogram. , 2014, , .		0
175	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	1.7	117
176	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. <i>Molecular Neurodegeneration</i> , 2014, 9, 38.	4.4	63
177	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.5	143
178	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	1.5	29
179	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. <i>Acta Neuropathologica</i> , 2014, 127, 397-406.	3.9	133
180	Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. <i>Brain Research</i> , 2014, 1584, 15-21.	1.1	70

#	ARTICLE	IF	CITATIONS
181	Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014, 35, 1769-1777.	1.5	48
182	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. <i>Neurobiology of Aging</i> , 2014, 35, 2421.e13-2421.e17.	1.5	74
183	Late-onset Alzheimer disease genetic variants in posterior cortical atrophy and posterior AD. <i>Neurology</i> , 2014, 82, 1455-1462.	1.5	51
184	Staging TDP-43 pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 441-450.	3.9	278
185	Primary age-related tauopathy (PART): a common pathology associated with human aging. <i>Acta Neuropathologica</i> , 2014, 128, 755-766.	3.9	1,060
186	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 1.	3.0	156
187	Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer's disease?. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 24.	3.0	35
188	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	3.9	336
189	TDP-43 in Alzheimer's disease is not associated with clinical FTD or Parkinsonism. <i>Journal of Neurology</i> , 2014, 261, 1344-1348.	1.8	22
190	Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. <i>Brain</i> , 2014, 137, 1533-1549.	3.7	100
191	Differential clinicopathologic and genetic features of late-onset amnesic dementias. <i>Acta Neuropathologica</i> , 2014, 128, 411-421.	3.9	119
192	TDP-43 AMPLIFIES MEMORY LOSS AND HIPPOCAMPAL ATROPHY IN ALZHEIMER'S DISEASE. , 2014, 10, P279-P280.		1
193	O1-01-01: PATHOLOGIC INVESTIGATION OF MICROINFARCTS AND ASSOCIATION WITH GRAY MATTER ATROPHY ON ANTEMORTEM MRI. , 2014, 10, P128-P128.		0
194	IC-P-066: PATHOLOGIC INVESTIGATION OF MICROINFARCTS AND ASSOCIATION WITH GRAY MATTER ATROPHY ON ANTEMORTEM MRI. , 2014, 10, P36-P37.		0
195	IC-02-04: EARLY, BUT NOT ADVANCED, NEUROFIBRILLARY TANGLE PATHOLOGY OR AMYLOID-B PATHOLOGY SIGNIFICANTLY ASSOCIATES WITH ABNORMAL HIPPOCAMPAL SIZE IN COGNITIVELY NORMAL ELDERLY. , 2014, 10, P5-P5.		0
196	O3-04-01: NEXT-GENERATION RNA SEQUENCING IN ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. , 2014, 10, P214-P215.		0
197	P1-202: HISTORY OF HEAD INJURY AND ALZHEIMER'S DISEASE (AD) NEUROPATHOLOGY. , 2014, 10, P377-P377.		0
198	Nonamnesic mild cognitive impairment progresses to dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 2032-2038.	1.5	191

#	ARTICLE	IF	CITATIONS
199	Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 978-988.	4.9	232
200	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 1681-1689.	1.5	58
201	Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. <i>Acta Neuropathologica</i> , 2013, 125, 289-302.	3.9	87
202	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 127-134.	0.8	53
203	Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. <i>Acta Neuropathologica</i> , 2013, 125, 741-752.	3.9	40
204	Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. <i>Sleep Medicine</i> , 2013, 14, 754-762.	0.8	326
205	Progressive amnesic dementia, hippocampal sclerosis, and mutation in C9ORF72. <i>Acta Neuropathologica</i> , 2013, 126, 545-554.	3.9	30
206	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. <i>Brain</i> , 2013, 136, 455-470.	3.7	37
207	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. <i>Neurology</i> , 2013, 81, 1332-1341.	1.5	84
208	Progressive Supranuclear Palsy: High-Field-Strength MR Microscopy in the Human Substantia Nigra and Globus Pallidus. <i>Radiology</i> , 2013, 266, 280-288.	3.6	26
209	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. <i>Neurology</i> , 2013, 80, 2076-2078.	1.5	31
210	Regional patterns of atrophy on MRI in Alzheimer's disease: Neuropsychological features and progression rates in the ADNI cohort. <i>Advances in Alzheimer's Disease</i> , 2013, 02, 135-147.	0.3	5
211	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. <i>Brain</i> , 2012, 135, 765-783.	3.7	322
212	A Quantitative Postmortem MRI Design Sensitive to White Matter Hyperintensity Differences and Their Relationship With Underlying Pathology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 1113-1122.	0.9	78
213	Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. <i>Acta Neuropathologica</i> , 2012, 124, 681-692.	3.9	103
214	O4: Differentiating clinicopathologic and genetic aspects of hippocampal sclerosis in Alzheimer's disease from limbic predominant Alzheimer's disease and "pure" hippocampal sclerosis. <i>Alzheimer's and Dementia</i> , 2012, 8, P620.	0.4	1
215	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	4.9	355
216	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. <i>Neurology</i> , 2012, 79, 553-560.	1.5	91

#	ARTICLE	IF	CITATIONS
217	Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 142-152.	1.8	72
218	Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. <i>Movement Disorders</i> , 2012, 27, 72-78.	2.2	99
219	Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. <i>Neuroscience Letters</i> , 2011, 491, 122-126.	1.0	53
220	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. <i>Lancet Neurology</i> , The, 2011, 10, 785-796.	4.9	733
221	A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2011, 122, 727-736.	3.9	4
222	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. <i>Acta Neuropathologica</i> , 2011, 122, 673-690.	3.9	277
223	Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau). <i>Journal of Molecular Neuroscience</i> , 2011, 45, 384-389.	1.1	295
224	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. <i>Brain</i> , 2011, 134, 3264-3275.	3.7	119
225	Functional Impact of White Matter Hyperintensities in Cognitively Normal Elderly Subjects. <i>Archives of Neurology</i> , 2010, 67, 1379-85.	4.9	146
226	An Increase in $\beta$ 42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice. <i>Current Alzheimer Research</i> , 2008, 5, 385-391.	0.7	29
227	MRI correlates of neurofibrillary tangle pathology at autopsy. <i>Neurology</i> , 2008, 71, 743-749.	1.5	312
228	Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice. <i>Neurobiology of Aging</i> , 2007, 28, 1248-1257.	1.5	43
229	Non-random distribution among a guild of parasitoids: implications for community structure and host survival. <i>Ecological Entomology</i> , 2006, 31, 557-563.	1.1	14
230	Development of the continuously variable volume reactor for flow injection analysis. <i>Analytica Chimica Acta</i> , 2002, 455, 287-304.	2.6	5
231	Linkage of frontotemporal dementia to chromosome 17: clinical and neuropathological characterization of phenotype. <i>American Journal of Human Genetics</i> , 1996, 59, 1306-12.	2.6	42